The efficacy of trastuzumab in Her-2eu-overexpressing metastatic breast cancer is independent of p53 status

Wolfgang J. Köstler; Thomas Brodowicz; Gernot Hudelist; Margaretha Rudas; Reinhard Horvat; Günther G. Steger; Christian F. Singer; Johannes Attems; Werner Rabitsch; Negar Fakhrai; Katarzyna Elandt; Christoph Wiltschke; Michael Hejna; Christoph C. Zielinski

首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >The efficacy of trastuzumab in Her-2eu-overexpressing metastatic breast cancer is independent of p53 status

【24h】

The efficacy of trastuzumab in Her-2eu-overexpressing metastatic breast cancer is independent of p53 status

机译：曲妥珠单抗在Her-2 / neu过表达的转移性乳腺癌中的疗效与p53状态无关

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Her-2eu and p53-mediated signalling have been shown to interact at various cellular levels. However, the clinical relevance of p53 alterations in patients receiving trastuzumab for Her-2eu-overexpressing metastatic breast cancer (MBC) remains unknown. The present study was performed to corroborate previous in vitro findings from our laboratory showing that trastuzumab induces growth arrest and apoptosis in a p53-independent manner.

机译：目的：已证明Her-2 / neu和p53介导的信号在各种细胞水平上相互作用。然而，接受曲妥珠单抗治疗的Her-2 / neu过表达转移性乳腺癌（MBC）患者中p53改变的临床相关性仍未知。进行本研究以证实我们实验室先前的体外发现，结果表明曲妥珠单抗以p53独立的方式诱导生长停滞和细胞凋亡。

著录项

来源
《Journal of Cancer Research and Clinical Oncology 》 |2005年第7期| 420-428| 共9页
作者
Wolfgang J. Köstler; Thomas Brodowicz; Gernot Hudelist; Margaretha Rudas; Reinhard Horvat; Günther G. Steger; Christian F. Singer; Johannes Attems; Werner Rabitsch; Negar Fakhrai; Katarzyna Elandt; Christoph Wiltschke; Michael Hejna; Christoph C. Zielinski;
展开▼
作者单位

Clinical Division of Oncology Department of Medicine I Medical University of ViennaCenter of Excellence for Clinical Experimental Oncology (CLEXO) Medical University of Vienna;

Clinical Division of Oncology Department of Medicine I Medical University of ViennaCenter of Excellence for Clinical Experimental Oncology (CLEXO) Medical University of Vienna;

Ludwig Boltzmann Institute for Clinical Experimental Oncology Medical University of Vienna;

Clinical Institute of Pathology Medical University of Vienna;

Clinical Institute of Pathology Medical University of Vienna;

Clinical Division of Oncology Department of Medicine I Medical University of ViennaCenter of Excellence for Clinical Experimental Oncology (CLEXO) Medical University of Vienna;

Center of Excellence for Clinical Experimental Oncology (CLEXO) Medical University of ViennaClinical Division of Special Gynecology Department of Gynecology and Obstetrics Medical University of Vienna;

Department of Pathology Otto Wagner Hospital;

Center of Excellence for Clinical Experimental Oncology (CLEXO) Medical University of ViennaBone Marrow Transplantation Unit Department of Medicine I Medical University of Vienna;

Clinical Division of Oncology Department of Medicine I Medical University of ViennaCenter of Excellence for Clinical Experimental Oncology (CLEXO) Medical University of Vienna;

Clinical Division of Oncology Department of Medicine I Medical University of ViennaCenter of Excellence for Clinical Experimental Oncology (CLEXO) Medical University of Vienna;

Clinical Division of Oncology Department of Medicine I Medical University of ViennaCenter of Excellence for Clinical Experimental Oncology (CLEXO) Medical University of Vienna;

Clinical Division of Oncology Department of Medicine I Medical University of ViennaCenter of Excellence for Clinical Experimental Oncology (CLEXO) Medical University of Vienna;

Clinical Division of Oncology Department of Medicine I Medical University of ViennaCenter of Excellence for Clinical Experimental Oncology (CLEXO) Medical University of ViennaLudwig Boltzmann Institute for Clinical Experimental Oncology Medical University of Vienna;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Her-2eu; Breast cancer; p53; Trastuzumab;

机译：Her-2 / neu;乳腺癌;p53;曲妥珠单抗;

相似文献

外文文献
中文文献
专利

1. The efficacy of trastuzumab in Her-2eu-overexpressing metastatic breast cancer is independent of p53 status. [J] . Kostler WJ, Brodowicz T, Hudelist G, Journal of Cancer Research and Clinical Oncology . 2005 ,第7期

机译：曲妥珠单抗在Her-2 / neu过表达的转移性乳腺癌中的疗效与p53状态无关。
2. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2eu-overexpressing metastatic breast cancer. [J] . Sawaki M, Ito Y, Tada K, Tumori. . 2004 ,第1期

机译：曲妥珠单抗作为单一药物在经过大量预处理的HER-2 / neu过表达转移性乳腺癌患者中的疗效和安全性。
3. Trastuzumab: targeted therapy for the management of HER-2eu-overexpressing metastatic breast cancer. [J] . Emens LA American journal of therapeutics . 2005 ,第3期

机译：曲妥珠单抗：靶向治疗HER-2 / neu过度表达的转移性乳腺癌的治疗。
4. Correlation Between Glycan Biomarkers of Human Breast Cancer and a Mouse Model of Metastatic Breast Cancer [C] . Maria Lorna A. de Leoz, Lawrence J. T. Young, Hyun Joo An, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：人乳腺癌甘油生物标志物与转移性乳腺癌小鼠模型的相关性
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [O] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, -1

机译：曲妥珠单抗氨丹宁在仅使用过曲妥珠单抗和帕妥珠单抗联合曲妥珠单抗治疗且仅在日本人群中治疗的转移性人类表皮生长因子受体2阳性乳腺癌患者之间的疗效比较
7. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [O] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, 2019

机译：血液抑制患者患者曲妥珠单抗疗效的疗效比较，所述转移性人体表皮生长因子患者2阳性乳腺癌及仅在日本人群中的曲妥珠单抗治疗

The efficacy of trastuzumab in Her-2eu-overexpressing metastatic breast cancer is independent of p53 status

摘要

著录项

相似文献

相关主题

期刊订阅